A pioneering diagnostic approach utilizing DNA methylation markers derived from bilateral nasal swabs offers a noninvasive, automated method to detect nasopharyngeal carcinoma (NPC) at early stages. Published in BMC Cancer, this technology leverages epigenetic profiling to improve screening accuracy and patient compliance, potentially transforming NPC diagnosis and enabling earlier therapeutic intervention in a cancer form with substantial geographic and demographic prevalence.